Search results for: hospital

ACR Releases COVID-19 Clinical Guidance for Pediatric Patients with Rheumatic Disease

Gretchen Henkel | July 8, 2020

The recommendations for pediatric rheumatology patients address various treatment options and provide general guidance, as well as direction for when to start, stop or reduce medications.

Bone Density Concerns: Guidance on Tackling Fracture Risk in CKD

Thomas R. Collins | July 7, 2020

Suggestions on how to assess risk and manage bone issues in chronic kidney disease patients are offered…

Biologic Treatment Recommendations for Rheumatic Disease Patients Who Contract COVID-19

Thomas R. Collins | July 7, 2020

COVID-19 Global Alliance registry and other data on rheumatic disease patients with COVID-19 were presented…

Caring for Pediatric Patients During a Pandemic: Q&A with Jay Mehta, MD

Mary Beth Nierengarten | July 6, 2020

Caring for pediatric patients during a pandemicin the age of COVID-19 requires adaptations, says Jay Mehta, MD, Children’s Hospital of Philadelphia. “The one exposure that seems to put [pediatric] patients at risk is if they are on higher doses of steroids, with some data suggesting worse outcomes. We just put out guidelines telling providers to reduce steroids in their patients to the lowest dose that can adequately control their disease.”

The ACR Releases New Telemedicine Position Statement

Carina Stanton | July 6, 2020

The rapid expansion of telemedicine in rheumatology, as well as changes to reimbursement and relaxed regulations, during the COVID-19 pandemic has served as an impetus for the ACR to review its position and release a new statement in support of optimized telemedicine practices.

Apremilast Promising for Plaque Psoriasis

Michele B. Kaufman, PharmD, BCGP | July 6, 2020

Apremilast has been shown to improve the signs and symptoms of mild to moderate plaque psoriasis in adults, according to new research…

In Memoriam … J. Timothy Harrington, MD, MACR: July 6, 1940–June 23, 2020

William Arnold, MD; Tim Bartholow, MD; Drew Johnson, MS, MBA; Joel Kremer, MD; Daniel Malone, MD; Eric D. Newman, MD; Kenneth Saag, MD; & Douglas White, MD | June 30, 2020

June saw the passing of a beloved colleague, mentor and friend to many in the rheumatology community when J. Timothy Harrington, MD, died of pancreatic cancer in his hometown of Madison, Wis. Dr. Harrington trained at Massachusetts General Hospital, the National Institutes of Health National Cancer Institute and UT Southwestern Medical Center, and served on…

ABX464 in Phase 2a Trials for RA

Michele B. Kaufman, PharmD, BCGP | June 29, 2020

Research is examining the safety and tolerability of two different doses of ABX464 in patients with moderate to severe active RA…

Research Beyond COVID-19: Collateral Damage

Nancy A. Delnay, MSN, CNP; Charmayne M. Dunlop-Thomas, MS, MPH; Rebecca J. Cleveland, PhD; Cynthia S. Crowson, PhD; Joshua Stefanik, MSPT, PhD; Jungwha Lee, PhD, MPH; Kendra Young, MSPH, PhD; & Dina L. Jones, PT, PhD | June 23, 2020

COVID-19 has generated an outpouring of fast-paced, late-breaking new developments. The majority of countries (188) around the world have reported cases of COVID-19.1 As of April 1, 2020, the Centers for Disease Control and Prevention had reported cases in every U.S. jurisdiction (50 states, District of Columbia, Puerto Rico, Guam, the Northern Mariana Islands and…

Zoledronate After Denosumab Does Not Fully Prevent Bone Loss

Marilynn Larkin | June 23, 2020

NEW YORK (Reuters Health)—In postmenopausal women and men treated for at least two years with denosumab, a single infusion of zoledronate given after denosumab discontinuation does not completely prevent bone turnover and loss, researchers say. Given the findings, “bone mineral density (BMD) should probably be higher than the current target for discontinuation of bisphosphonate treatment…